ReviewCritical reviews in biochemistry and molecular biology2017
Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet.
Review in Critical reviews in biochemistry and molecular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Noncanonical chromosomal-end-specific telomeric repeat arrays in naturally telomerase-negative yeasts.Nucleic acids research · 2026Article
- Beginning at the ends: telomere and telomere-based cancer therapeutics.Molecular genetics and genomics : MGG · 2024Review
- R-loops' m6A modification and its roles in cancers.Molecular cancer · 2024Review
- Review
- The multistep path to replicative senescence onset: zooming on triggering and inhibitory events at telomeric DNA.Frontiers in cell and developmental biology · 2023Review
- METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability.Nucleic acids research · 2022Article
- Identification of theCells · 2022Article
- Consecutive Inhibition of Telomerase and Alternative Lengthening Pathway Promotes Hodgkin's Lymphoma Cell Death.Biomedicines · 2022Article
- Ultrastructure and nuclear architecture of telomeric chromatin revealed by correlative light and electron microscopy.Nucleic acids research · 2022Article
- Regulation of Replication Stress in Alternative Lengthening of Telomeres by Fanconi Anaemia Protein.Genes · 2022Review
- The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma.Cancer medicine · 2021Article
- A Role for Human DNA Polymerase λ in Alternative Lengthening of Telomeres.International journal of molecular sciences · 2021Article
- The Connection Between Cell Fate and Telomere.Advances in experimental medicine and biology · 2021Review
- Review
- FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops.Scientific reports · 2019Article
- Article
- TASks for subtelomeres: when nucleosome loss and genome instability are favored.Current genetics · 2019Review
- Transcription-mediated replication hindrance: a major driver of genome instability.Genes & development · 2019Review
- Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.Cell death & disease · 2019Article
- FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
While most cancer cells rely on telomerase expression/re-activation for linear chromosome maintenance and sustained proliferation, a significant population of cancers (10-15%) employs telomerase-independent strategies, collectively dubbed Alternative Lengthening of Telomeres (ALT). Most ALT cells relax the usual role of telomeres as inhibitors of local homologous recombination while maintaining the ability of telomeres to prohibit local non-homologous end joining reactions. Here we review current concepts surrounding how ALT telomeres achieve this new balance via alterations in chromatin landscape, DNA damage repair processes and handling of telomeric transcription. We also discuss telomerase independent end maintenance strategies utilized by other organisms, including fruitflies and yeasts, to draw parallels and contrasts and highlight additional modes, beyond ALT, that may be available to telomerase-minus cancers. We conclude by commenting on promises and challenges in the development of effective anti-ALT cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.